Biotech: Page 37
-
Dilok Klaisataporn
BioAge raises $170M to back Phase 2-ready obesity drug
BioAge’s Series D will fund a study combining its medicine with Eli Lilly’s Zepbound, a strategy the company hopes could help people lose weight while maintaining muscle mass.
By Jonathan Gardner • Feb. 13, 2024 -
Permission granted by Biogen
New Alzheimer's drugsBiogen has a fuzzy line of sight on prized Alzheimer’s drug
CEO Chris Viehbacher said there are about 3,800 U.S. patients on a registry for Leqembi. But Biogen doesn’t have all the details, as development partner Eisai is leading commercial efforts.
By Jacob Bell • Feb. 13, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Getty Images
ADC startup ProfoundBio, led by Seagen veterans, raises $112M
The Series B round will fund development of antibody-drug conjugates now in clinical testing, among them a rival to AbbVie’s ovarian cancer drug Elahere.
By Gwendolyn Wu • Feb. 13, 2024 -
Permission granted by GV
Q&ATwo GV investors on biotech’s reset and building their next drug startups
Newly named general partner Anthony Philippakis and managing partner Krishna Yeshwant discussed biotech’s newfound optimism and their investing “North Star.”
By Gwendolyn Wu • Feb. 13, 2024 -
Elizabeth Regan/BioPharma Dive
Kalvista pill succeeds in late-stage study for rare swelling disorder
The biotech's drug quickly alleviated symptoms of the swelling attacks associated with hereditary angioedema, supporting the idea it could be an oral alternative to existing medicines.
By Ben Fidler • Updated Feb. 13, 2024 -
Getty Images
Alys launches with $100M and a pipeline of skin disease drugs
European venture firm Medicxi built the startup by combining six of its portfolio companies, similar to when it merged 10 startups to form Centessa Pharmaceuticals in 2021.
By Delilah Alvarado • Feb. 12, 2024 -
Permission granted by Kyverna Therapeutics
Q&A // Emerging biotechKyverna CEO Peter Maag on courting investors in a ‘volatile’ IPO market
After the CAR-T company priced one of the sector’s largest IPOs in recent years, Maag spoke with BioPharma Dive about what it takes to go public now.
By Ben Fidler • Feb. 9, 2024 -
Getty Images
Gene editing biotech Metagenomi pulls off nearly $94M IPO
The company is one of just three preclinical biotechs to go public since last summer, but it raised significantly less than others that debuted with more advanced medicines.
By Gwendolyn Wu • Feb. 8, 2024 -
Getty Images
Neurona raises another $120M for brain disease cell therapies
The company’s haul is the latest sign brain drugs are recapturing the interest of investors after years of being passed over for other areas of research.
By Jacob Bell • Feb. 8, 2024 -
Thomas Lohnes via Getty Images
BioNTech partners with Autolus to boost cell therapy manufacturing
The German biotech will invest $200 million in Autolus — funds that, along with a $50 million fee, give it licensing options and access to supply infrastructure.
By Kristin Jensen • Feb. 8, 2024 -
Getty Images
Kyverna IPO adds to biotech momentum with $319M fundraise
The company, a leading developer of cell therapies for autoimmune diseases, is the fifth drug startup to go public in 2024. All raised at least $100 million.
By Ben Fidler • Feb. 7, 2024 -
Getty Images
BridgeBio sells partial rights to dwarfism drug for $100M
The deal hands Kyowa Kirin rights in Japan to the drug, which is emerging as a potential rival to BioMarin’s marketed medicine Voxzogo.
By Delilah Alvarado • Feb. 7, 2024 -
Permission granted by Scion Life Sciences
Venture firm Scion Life Sciences launches with $310M to back new biotechs
The new firm intends to carefully select its startups and fund them for the long haul. “We're not a company formation factory,” said co-founder Aaron Kantoff.
By Gwendolyn Wu • Feb. 7, 2024 -
Permission granted by Khosla Ventures
Q&AKhosla Ventures’ Alex Morgan on biotech’s challenges and solving drug delivery
The life sciences investor has backed a number of startups working on technologies for delivering and manufacturing cell and gene medicines.
By Gwendolyn Wu • Feb. 6, 2024 -
Valneva sells regulatory ‘fast pass’ for $103M
The company said it will invest the sale proceeds into testing of an experimental Lyme disease shot and of Ixchiq, its new chikungunya vaccine.
By Delilah Alvarado • Feb. 5, 2024 -
Getty Images
Arch, a prolific biotech creator, is raising $3B for startup investing
A regulatory filing shows the firm is putting together a new multibillion-dollar fund, roughly two years after raising a similar amount.
By Ben Fidler • Feb. 2, 2024 -
Spencer Platt via Getty Images
Brain drug developer Alto Neuroscience prices $129M IPO
The biotech was joined by Fractyl Health in pricing an IPO Thursday evening, adding to last month’s stock offerings from CG Oncology and Arrivent BioPharma.
By Gwendolyn Wu • Feb. 2, 2024 -
Michael M. Santiago via Getty Images
Avrobio’s road ends in reverse merger with Tim Springer-backed startup
The gene therapy developer’s demise has given Tectonic Therapeutic, a GPCR-focused startup founded by the prolific biotech entrepreneur, an alternate path to the public markets.
By Kristin Jensen • Jan. 31, 2024 -
Getty Images
Cour gets $105M, pharma help to ‘reprogram’ autoimmune disease
Roche, Pfizer and Bristol Myers Squibb have all invested in the startup, which is using nanoparticle technology to retrain the body’s immune system.
By Ben Fidler • Jan. 30, 2024 -
Courtesy of Regeneron Pharmaceuticals
Regeneron to acquire 2seventy’s cell therapy pipeline
About 150 of the smaller company's employees will also transition to Regeneron, which is setting up a new cellular medicines research and development unit.
By Ned Pagliarulo • Jan. 30, 2024 -
Permission granted by Vertex Pharmaceuticals
Non-opioid drug from Vertex cuts pain in major trial tests
While the overall results were positive, the drug fell short in both studies on a secondary goal comparing it to a widely prescribed opioid.
By Ned Pagliarulo • Jan. 30, 2024 -
Getty Images
Deep Dive // State of PlayCAR-T for lupus: the ‘tip of the iceberg’ for cell therapy in autoimmune disease
Since a landmark paper in 2022, drugmakers have begun nearly a dozen trials of cell therapies for lupus, with more set to start. Here’s why their efforts are worth watching.
By Ben Fidler • Jan. 30, 2024 -
Carl Court via Getty Images
PTC Duchenne drug approval set to be revoked in Europe
The EMA’s drugs committee again recommended rescinding an OK for Translarna, which was cleared in 2014 despite questions about its benefit.
By Ben Fidler • Jan. 26, 2024 -
Michael M. Santiago via Getty Images
Cancer drugmaker ArriVent follows on CG’s heels with $175M IPO
The company is developing an oral alternative to J&J’s lung cancer medicine Rybrevant, and adds to a trend of late-stage drugmakers finding investor demand on Wall Street.
By Ben Fidler • Jan. 25, 2024 -
Permission granted by Bristol-Myers Squibb
RayzeBio drew other pharma interest before Bristol Myers deal
Two “global biopharmaceutical companies” made bids to buy the radiopharma specialist, but lost out to Bristol Myers, which negotiated aggressively to secure a $4.1 billion buyout.
By Ned Pagliarulo • Jan. 25, 2024
Previous
